https://www.selleckchem.com/pr....oducts/brefeldin-a.h
5 ± 2.0 vs. 0.2 ± 0.4; p 0.001). Continuing anti-VEGF therapy after achieving functional and morphological stability every 12-14 weeks does not prevent recurrences. Patients deserve to be informed of a potential lifetime risk of recurrences, even under continued therapy. Continuing anti-VEGF therapy after achieving functional and morphological stability every 12-14 weeks does not prevent recurrences. Patients deserve to be informed of a potential lifetime risk of recurrences, even under continued therapy. To investigate the res
Like
Comment
Share
